IFNG and neoplasm: Preclinical data involving pegilodecakin in IL-10−/− mice with chemically induced skin cancers showed that a single dose of systemic pegilodecakin led to increased IFNγ level and cytotoxic T cells, tumor regression, and durable immune memory when mice were rechallenged with tumor cells up to 8 months later [362].